citric acid, anhydrous and Acute Kidney Injury studies

Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.

Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.

Research Excerpts

Excerpt	Relevance	Reference
"The concentration of high-dose meropenem (2 g every 8 h) administered in a prolonged infusion was similar before and after the introduction of RCA-CVVHD in patients with sepsis who developed acute kidney injury."	7.96	Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. ( Czuczwar, M; Fronczek, J; Gielicz, A; Górka, J; Kudliński, B; Nowak-Kózka, I; Polok, KJ; Seczyńska, B; Szczeklik, W, 2020)
"The concentration of high-dose meropenem (2 g every 8 h) administered in a prolonged infusion was similar before and after the introduction of RCA-CVVHD in patients with sepsis who developed acute kidney injury."	3.96	Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. ( Czuczwar, M; Fronczek, J; Gielicz, A; Górka, J; Kudliński, B; Nowak-Kózka, I; Polok, KJ; Seczyńska, B; Szczeklik, W, 2020)
"To describe our experience with a newly implemented RCA protocol with acid citrate dextrose formula A (ACD-A) and intravenous calcium gluconate, for use with PrismaFlex CRRT in critically ill patients with acute kidney injury."	3.75	Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. ( Bailie, T; Burry, LD; Carvalhana, V; Hallett, D; Lapinsky, SE; Lee, D; Mehta, S; Ramganesh, S; Richardson, R; Tung, DD, 2009)
"The authors report the development of a rapidly progressive encephalopathy marked by confusion, myoclonus, seizures, coma, and death in a group of women with renal failure who received an oral solution of citrate and aluminum hydroxide gel concurrently."	3.67	Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. ( Kirschbaum, BB; Schoolwerth, AC, 1989)
"Acute kidney injury was associated with significant changes in the surface expression of CD182 and CD16 throughout CVVH treatment, independent of the anticoagulation regime."	3.11	Analysis of Leukocyte Recruitment in Continuous Veno-Venous Hemofiltration with Regional Citrate vs. Systemic Heparin Anticoagulation. ( Küllmar, M; Liu, C; Margraf, A; Meersch, M; Rossaint, J; Zarbock, A, 2022)
" Citrate anticoagulation contributes to improved renal function and extended filter usage and reduces the incidence of adverse bleeding reactions."	3.01	Efficacy and Safety of Citric Acid and Heparin Anticoagulation in Patients with Septic Acute Kidney Injury Undergoing Continuous Renal Replacement Therapy: A Meta-Analysis. ( Cai, Q; Huang, J; Lin, S; Lin, Y; Sun, X; Xiao, M; Yao, J, 2023)
"SLED under regional citrate anticoagulation is safe and effective."	2.78	[The safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis]. ( Chen, ZW; Fu, P; Liao, YJ; Tang, Y; Wang, TL; Yang, YY; Zhang, L; Zhao, YL, 2013)
"ICU patients with acute renal failure requiring continuous renal replacement therapy, without cirrhosis, severe coagulopathy, or known sensitivity to heparin."	2.71	Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. ( Berghmans, D; Canivet, JL; Damas, P; Dubois, B; Ledoux, D; Monchi, M, 2004)
" The interruption may impair the solute clearance as it causes under dosing of CRRT."	2.66	Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. ( Akazawa, M; Fujii, T; Kataoka, Y; Nakata, Y; Takahashi, S; Tsujimoto, H; Tsujimoto, Y, 2020)
"Management of coronavirus disease 2019-associated acute kidney injury with kidney replacement therapy should follow existing recommendations regarding modality, dose, and timing of initiation."	2.66	Management of Acute Kidney Injury in Coronavirus Disease 2019. ( Matzumura Umemoto, G; Shaikh, S; Vijayan, A, 2020)
" The interruption may impair the solute clearance as it causes under dosing of CRRT."	2.66	Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. ( Akazawa, M; Fujii, T; Kataoka, Y; Nakata, Y; Takahashi, S; Tsujimoto, H; Tsujimoto, Y, 2020)
"Patients with acute kidney injury are generally prothrombotic, and as such prone to increased risk of clotting in extracorporeal renal replacement therapy (RRT) circuits."	2.53	Anticoagulation for renal replacement therapy for patients with acute kidney injury. ( Davenport, A; Nongnuch, A; Tangsujaritvijit, V, 2016)
"After discussing the various causes of acute renal failure in children and infants, this review focuses on recent advancements in the management of acute renal failure, including acute dialysis modalities and continuous renal replacement therapy."	2.42	Acute renal failure in children and infants. ( Barletta, GM; Bunchman, TE, 2004)
"Yucatan minipigs (8-15 kg) with induced septic shock underwent continuous hemodiafiltration with the CARPEDIEM™ pediatric hemodialysis system using regional citrate anticoagulation (RCA) with or without SCD (n = 5 per group)."	1.91	Immunomodulatory therapy using a pediatric dialysis system ameliorates septic shock in miniature pigs. ( Chan, G; Goldstein, SL; Humes, HD; Johnston, KA; Ketteler, SK; Pino, CJ, 2023)
" Dosing regimens were independently selected by intensivists."	1.91	Clearance of Piperacillin-Tazobactam and Vancomycin During Continuous Renal Replacement With Regional Citrate Anticoagulation. ( Ankravs, MJ; Bellomo, R; Deane, AM; Rechnitzer, T; Roberts, JA; Sharrock, L; Wallis, SC, 2023)
"Hypophosphatemia is a common electrolyte disorder in critically ill patients undergoing prolonged kidney replacement therapy (KRT)."	1.91	Simplified regional citrate anticoagulation protocol for CVVH, CVVHDF and SLED focused on the prevention of KRT-related hypophosphatemia while optimizing acid-base balance. ( Di Mario, F; Fiaccadori, E; Greco, P; Italiano, C; Maccari, C; Morabito, S; Pacchiarini, MC; Pistolesi, V; Regolisti, G; Sabatino, A; Vizzini, G, 2023)
"Liver failure is a rapidly progressive condition with a high mortality rate."	1.56	[Research progress of the application of regional citrate anticoagulation in artificial liver to treat liver failure]. ( Bai, L; Ma, YJ; Tang, H, 2020)
"Critically ill coronavirus disease 2019 (COVID-19) patients have a high risk of acute kidney injury (AKI) that requires renal replacement therapy (RRT)."	1.56	Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. ( Arnold, F; Biever, PM; Kalbhenn, J; Neumann-Haefelin, E; Rieg, S; Tanriver, Y; Walz, G; Westermann, L, 2020)
"In 11 patients with septic shock and acute kidney injury stage 3, we studied 12 cycles of cytokine adsorption and regional citrate anticoagulation-continuous veno-venous hemodialysis."	1.56	Feasibility and safety of combined cytokine adsorption and continuous veno-venous hemodialysis with regional citrate anticoagulation in patients with septic shock. ( Brandenburger, T; Dimski, T; Kindgen-Milles, D; Slowinski, T, 2020)
" Citrate was dosed at median 2."	1.51	Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. ( Chua, HR; Haroon, SWP; Lau, T; Lee, N; Mukhopadhyay, A; Murali, TM; Phua, J; Tan, JN; Tan, ZY, 2019)
"One hundred twenty two consecutive ICU cancer patients with AKI treated with citrate-based CVVHD were prospectively evaluated in this prospective observational study."	1.48	Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury. ( Bezerra, JS; Burdmann, EA; Caires, RA; Costa E Silva, VT; Costalonga, EC; Fukushima, JT; Hajjar, LA; Oikawa, L; Oliveira Coelho, F; Oliveira, APL; Soares, CM, 2018)
" Our results, though on a small series of patients, provide evidence that CRRT with citrate can be a safe and promising treatment for AKI after LT."	1.46	Safety and Efficacy of Citrate Anticoagulation for Continuous Renal Replacement Therapy for Acute Kidney Injury After Liver Transplantation: A Single-Center Experience. ( Carraro, A; Cicciarella, L; Lupo, A; Montin, U; Pertica, N; Violi, P; Zaza, G, 2017)
"Fifteen septic shock patients with acute kidney injury undergoing CPFA with RCA at target circuit citratemia of 6 mmol/L were treated with CPFA-haemofiltration in pure predilution (CPFA-HF predilution group, n = 5 patients), or predilution haemodiafiltration (CPFA-HDF predilution group, n = 5 patients) or pre- and postdilution haemofiltration (CPFA-HF pre/postdilution group, n = 5 patients)."	1.42	Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption. ( Agostini, F; Biancone, L; Holló, Z; Mariano, F; Morselli, M; Stella, M, 2015)
" Citrate pharmacokinetic data can provide a basis for the clinical use of predicting the risk of citrate accumulation."	1.39	Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury. ( Ding, F; Gu, Y; Hao, C; Jiao, Z; Liu, J; Qian, J; Xu, Z; You, H; Zheng, Y; Zhu, Q, 2013)
"This study protocol affords efficacious and safe anticoagulation of the SLED circuit, avoiding citrate accumulation and, in most patients, systematic calcium supplementation; it can be implemented with commercial citrate solutions, standard dialysis equipment, on-line produced dialysis fluid, and minimal laboratory monitoring."	1.39	Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. ( Barbagallo, M; Cabassi, A; Cademartiri, C; Castellano, G; Fiaccadori, E; Gherli, T; Maggiore, U; Morabito, S; Picetti, E; Regolisti, G, 2013)
"Ten patients with acute renal failure were evaluated."	1.38	Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution. ( Chan, KC; Shum, HP; Yan, WW, 2012)
"Rhabdomyolysis was caused by infection in two patients, by a statin in one patient and a non-traumatic crush in another, and followed cardiovascular surgery in two others."	1.37	High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. ( Buturović-Ponikvar, J; Kovač, J; Ponikvar, R; Premru, V, 2011)
"Twenty patients with acute renal failure on mechanical ventilation were treated, four for eight hours, four for 24 hours and 12 as long they needed continuous renal replacement therapy (9."	1.34	Continuous venovenous haemofiltration using a citrate buffered substitution fluid. ( Grabensee, B; Hennersdorf, M; Hetzel, GR; Plum, J; Schmitz, M; Sucker, C; Taskaya, G, 2007)
"Thirty critically ill patients with acute renal failure at risk of bleeding or with a major contraindication to heparin-CVVH and/or short filter life."	1.33	Low-dose citrate continuous veno-venous hemofiltration (CVVH) and acid-base balance. ( Baldwin, I; Bellomo, R; Cole, L; Egi, M; Fealy, N; French, C; Naka, T; Wan, L, 2005)
"A 72-year-old patient with multiple myeloma was admitted to the intensive care unit because of hypercalcemic crisis and acute renal failure."	1.30	Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. ( Hora, P; Matĕjovic, M; Nalos, M; Novák, I; Pittrová, H; Rokyta, R; Srámek, V, 1998)
" Regional citrate anticoagulation is a safe and effective method of performing hemodialysis in patients with acute renal failure at increased risk of bleeding."	1.28	Safety of regional citrate hemodialysis in acute renal failure. ( Diederich, D; Lohr, JW; Slusher, S, 1989)

Research

Studies (135)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

Filter Life

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (2.22)	18.7374
1990's	6 (4.44)	18.2507
2000's	17 (12.59)	29.6817
2010's	58 (42.96)	24.3611
2020's	51 (37.78)	2.80

Authors	Studies
Cassina, T	1
Villa, M	1
Soldani-Agnello, A	1
Zini, P	1
Nalesso, F	1
Gobbi, L	1
Cattarin, L	1
Innico, G	1
Calò, LA	1
Zhang, W	1
Bai, M	1
Zhang, L	4
Yu, Y	1
Li, Y	3
Zhao, L	1
Yue, Y	1
Zhang, M	1
Fu, P	4
Sun, S	1
Chen, X	1
Kośka, A	1
Kowalik, MM	1
Lango-Maziarz, A	1
Karolak, W	1
Jagielak, D	1
Lango, R	1
Wang, ZY	1
Feng, SH	1
Fan, BL	1
Ma, W	1
Jia, XC	1
Geng, H	1
Anantharaman, S	1
Chionh, CY	1
Chiao, C	1
Faust, H	1
Singh, T	1
Li, N	1
Miao, XL	1
Wu, BY	1
Miyaji, MJ	1
Ide, K	1
Takashima, K	1
Maeno, M	1
Krallman, KA	1
Lazear, D	1
Goldstein, SL	2
Li, R	1
Gao, X	1
Zhou, T	1
Wang, J	1
Zhang, P	1
Trakarnvanich, T	1
Sirivongrangson, P	1
Trongtrakul, K	1
Srisawat, N	3
Johnston, KA	1
Pino, CJ	1
Chan, G	1
Ketteler, SK	1
Humes, HD	2
Liet, JM	1
Baleine, J	1
Demaret, P	1
Mounier, S	1
Porcheret, F	1
Joram, N	1
Chenouard, A	1
Whiting, L	1
Bianchi, NA	1
Alouazen, K	1
Joannes-Boyau, O	1
Chiche, JD	1
Schneider, A	1
Margraf, A	1
Liu, C	3
Küllmar, M	3
Meersch, M	3
Rossaint, J	1
Zarbock, A	4
He, J	1
Xiao, Z	1
Zhou, X	1
Cao, J	1
Kang, X	1
Zhang, X	1
Sharrock, L	1
Ankravs, MJ	1
Deane, AM	1
Rechnitzer, T	1
Wallis, SC	1
Roberts, JA	1
Bellomo, R	4
Scherer, PF	1
Barbeiro, BG	1
Ammirati, AL	1
Dos Santos, BFC	1
Monte, JCM	1
Batista, MC	1
Doher, MP	1
Dos Santos, OFP	1
Matsui, TN	1
Gonçalves, VP	1
de Souza Durão, M	1
Frías, A	1
Gacitúa, I	1
Torres, R	1
Toro, L	1
Segovia, E	1
Alvo, M	1
Rodríguez, J	1
Romero, C	1
Sanhueza, ME	1
Doidge, JC	2
Gould, DW	2
Sadique, Z	2
Borthwick, M	2
Hatch, RA	2
Caskey, FJ	2
Forni, L	2
Lawrence, RF	2
MacEwan, C	2
Ostermann, M	3
Mouncey, PR	2
Harrison, DA	2
Rowan, KM	2
Young, JD	2
Watkinson, PJ	2
Wechselberger, S	1
Compton, F	1
Schilling, J	1
Kameda, S	1
Fujii, T	3
Ikeda, J	1
Kageyama, A	1
Takagi, T	1
Miyayama, N	1
Asano, K	1
Endo, A	1
Uezono, S	1
Ratanarat, R	1
Phairatwet, P	1
Khansompop, S	1
Naorungroj, T	1
Kaewdoungtien, P	1
Tachaboon, S	1
Kangsumrith, N	1
Di Mario, F	2
Sabatino, A	1
Regolisti, G	3
Pacchiarini, MC	1
Greco, P	2
Maccari, C	2
Vizzini, G	1
Italiano, C	1
Pistolesi, V	3
Morabito, S	4
Fiaccadori, E	4
González-Fernández, M	1
Quílez-Trasobares, N	1
Barea-Mendoza, JA	1
Molina-Collado, Z	1
Arias-Verdú, D	1
Barrueco-Francioni, J	1
Seller-Pérez, G	1
Herrera-Gutiérrez, ME	1
Sánchez-Izquierdo Riera, JA	1
Cappoli, A	1
Labbadia, R	1
Antonucci, L	1
Bottari, G	1
Rossetti, E	1
Guzzo, I	1
Zhou, Z	1
Yang, Y	1
Wang, F	2
Guo, L	1
Hu, Y	1
Zeng, Q	2
Yang, X	1
Liu, J	2
Liu, Z	2
Zhao, T	1
Su, T	1
Jin, Q	1
Lin, S	1
Xiao, M	1
Cai, Q	1
Lin, Y	1
Yao, J	1
Sun, X	1
Huang, J	1
Vieira, JAM	1
Reinheimer, IC	1
Dos Santos, AC	1
Halperin, FK	1
Susin, LA	1
Staub, LP	1
Ribeiro, RJE	1
da Silveira, JB	1
Fontoura, LF	1
de Souza, DC	1
Nunes, KP	1
de Souza, VC	1
da Silva Selistre, L	1
Poli-de-Figueiredo, CE	1
Bai, K	1
Zhou, F	1
Xu, F	1
Dang, H	1
Mariano, F	3
Hollo', Z	1
Depetris, N	1
Malvasio, V	1
Mella, A	1
Bergamo, D	1
Pensa, A	1
Berardino, M	1
Stella, M	3
Biancone, L	2
Nowak-Kózka, I	1
Polok, KJ	1
Górka, J	1
Fronczek, J	1
Gielicz, A	1
Seczyńska, B	1
Czuczwar, M	1
Kudliński, B	1
Szczeklik, W	1
Muhle-Goll, C	1
Eisenmann, P	1
Luy, B	1
Kölker, S	1
Tönshoff, B	1
Fichtner, A	1
Westhoff, JH	1
Tsujimoto, H	2
Tsujimoto, Y	2
Nakata, Y	2
Takahashi, S	2
Akazawa, M	2
Kataoka, Y	2
Ma, YJ	1
Bai, L	1
Tang, H	1
Shankaranarayanan, D	1
Muthukumar, T	1
Barbar, T	1
Bhasin, A	1
Gerardine, S	1
Lamba, P	1
Leuprecht, L	1
Neupane, SP	1
Salinas, T	1
Shimonov, D	1
Varma, E	1
Liu, F	1
Kindgen-Milles, D	7
Wempe, C	2
Gerss, J	2
Brandenburger, T	4
Dimski, T	4
Tyczynski, B	1
Jahn, M	1
Mülling, N	1
Mehrländer, M	1
Rosenberger, P	1
Marx, G	2
Simon, TP	1
Jaschinski, U	1
Deetjen, P	1
Putensen, C	1
Schewe, JC	1
Kluge, S	2
Jarczak, D	1
Slowinski, T	7
Bodenstein, M	1
Meybohm, P	1
Wirtz, S	1
Moerer, O	1
Kortgen, A	2
Simon, P	1
Bagshaw, SM	1
Kellum, JA	1
Arnold, F	1
Westermann, L	1
Rieg, S	1
Neumann-Haefelin, E	1
Biever, PM	1
Walz, G	1
Kalbhenn, J	1
Tanriver, Y	1
Ruiz, EF	1
Ortiz-Soriano, VM	1
Talbott, M	1
Klein, BA	1
Thompson Bastin, ML	1
Mayer, KP	1
Price, EB	1
Dorfman, R	1
Adams, BN	1
Fryman, L	1
Neyra, JA	1
Shaikh, S	1
Matzumura Umemoto, G	1
Vijayan, A	1
Hellman, T	1
Uusalo, P	1
Järvisalo, MJ	1
Di Maria, A	1
Parmigiani, A	1
Benigno, GD	1
Picetti, E	2
Barbagallo, M	2
Khoo, BZE	1
Lim, RS	1
See, YP	1
Yeo, SC	1
Chen, Z	2
Wang, H	1
Wu, Z	1
Jin, M	1
Chen, Y	1
Li, J	1
Wei, Q	1
Tao, S	1
Warnar, C	1
Faber, E	1
Katinakis, PA	1
Schermer, T	1
Spronk, PE	1
Rabbani, A	1
Dalili, N	1
Ashrafi, S	1
Hassanzadeh, K	1
Aliabbar, S	1
Nikeghbalian, S	1
Malekhoseini, SA	1
Nadiri, A	1
Valle, EO	1
Cabrera, CPS	1
Albuquerque, CCC	1
Silva, GVD	1
Oliveira, MFA	1
Sales, GTM	1
Smolentzov, I	1
Reichert, BV	1
Andrade, L	1
Seabra, VF	1
Lins, PRG	1
Rodrigues, CE	1
Tan, JN	1
Haroon, SWP	1
Mukhopadhyay, A	1
Lau, T	1
Murali, TM	1
Phua, J	1
Tan, ZY	1
Lee, N	1
Chua, HR	1
Bienholz, A	2
Reis, J	1
Sanli, P	1
de Groot, H	1
Petrat, F	1
Guberina, H	1
Wilde, B	1
Witzke, O	1
Saner, FH	1
Kribben, A	3
Weinberg, JM	1
Feldkamp, T	2
Pertica, N	1
Cicciarella, L	1
Carraro, A	1
Montin, U	1
Violi, P	1
Lupo, A	1
Zaza, G	1
Raymakers-Janssen, PAMA	1
Lilien, M	1
van Kessel, IA	1
Veldhoen, ES	1
Wösten-van Asperen, RM	1
van Gestel, JPJ	1
Huguet, M	1
Rodas, L	1
Blasco, M	1
Quintana, LF	1
Mercadal, J	1
Ortiz-Pérez, JT	1
Rovira, I	1
Poch, E	1
Fisher, R	1
Lei, K	1
Mitchell, MJ	1
Moore, GW	1
Dickie, H	1
Tovey, L	1
Crichton, S	1
Schneider, AG	1
Journois, D	1
Rimmelé, T	2
Datzmann, T	1
Träger, K	1
Schröppel, B	1
Reinelt, H	1
von Freyberg, P	1
Bokhari, SR	1
Siriki, R	1
Teran, FJ	1
Batuman, V	1
Schmitz, M	3
Joannidis, M	1
Czock, D	1
John, S	1
Jörres, A	1
Klein, SJ	1
Oppert, M	1
Schwenger, V	1
Kielstein, J	1
Willam, C	1
Costa E Silva, VT	1
Caires, RA	1
Bezerra, JS	1
Costalonga, EC	1
Oliveira, APL	1
Oliveira Coelho, F	1
Fukushima, JT	1
Soares, CM	1
Oikawa, L	1
Hajjar, LA	1
Burdmann, EA	1
Buter, H	1
Koopmans, M	2
van der Voort, PHJ	1
Ning, QQ	1
Meng, QH	1
Zhu, YK	1
Alvarez, G	1
Chrusch, C	1
Hulme, T	1
Posadas-Calleja, JG	1
Ricci, D	1
Panicali, L	1
Cavallari, G	1
Facchini, MG	1
Mancini, E	1
Gao, J	1
Wang, Y	1
Jin, D	1
Tang, L	1
Pan, K	1
Dissanayake, CU	1
Bharat, CI	1
Roberts, BL	1
Anstey, MH	1
Kalb, R	1
Kram, R	1
Morgera, S	2
Zheng, Y	2
Xu, Z	1
Zhu, Q	1
Qian, J	1
You, H	1
Gu, Y	1
Hao, C	1
Jiao, Z	1
Ding, F	2
Cademartiri, C	1
Cabassi, A	1
Gherli, T	1
Castellano, G	1
Maggiore, U	1
Wang, TL	1
Zhao, YL	1
Chen, ZW	1
Tang, Y	1
Yang, YY	1
Liao, YJ	1
Tritapepe, L	2
Vitaliano, E	1
Zeppilli, L	2
Polistena, F	2
Pierucci, A	2
Ricci, Z	1
Ronco, C	1
Soltysiak, J	1
Warzywoda, A	1
Kociński, B	1
Ostalska-Nowicka, D	1
Benedyk, A	1
Silska-Dittmar, M	1
Zachwieja, J	1
Khadzhynov, D	1
Schelter, C	1
Lieker, I	1
Mika, A	1
Staeck, O	1
Neumayer, HH	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
Citrate Versus Heparin in Continuous Renal Replacement Therapy : Effect on Cardiovascular System and Clot Circuit in Critically Ill Patients[NCT04865510]		41 participants (Actual)	Interventional	2019-02-04	Completed
Built-in Calculator Optimizes Continuous Veno-venous Hemofiltration Prescription and Improves Therapeutic Quality in Critically-ill Acute Kidney Injury Patients[NCT05638711]		1 participants (Actual)	Observational	2019-01-01	Completed
Evaluation of Filters Useful Life, Metabolic Control, Electrolyte Profile and Acid-base Balance During Regional Anticoagulation With 4% Trisodium Citrate in Patients Undergoing CVVHDF: Effects of Increased Blood Flow[NCT05796661]		27 participants (Anticipated)	Interventional	2023-01-09	Recruiting
Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy During Veno-venous ECMO: a Crossover Randomized Controlled Study[NCT05148026]		20 participants (Anticipated)	Interventional	2021-11-14	Recruiting
Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury[NCT02669589]	Phase 4	638 participants (Actual)	Interventional	2016-03-31	Completed
Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances[NCT01839578]		30 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU = Multicentre, Controlled, Randomised Superiority Trial[NCT01962116]	Phase 3	405 participants (Actual)	Interventional	2013-06-14	Completed
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273]	Phase 4	215 participants (Actual)	Interventional	2003-03-31	Completed
Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial[NCT00209378]		139 participants (Actual)	Interventional	2005-05-31	Completed
A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU[NCT01318811]	Phase 4	12 participants (Actual)	Interventional	2011-03-31	Terminated (stopped due to lack of recruitment)
Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial[NCT00798525]	Phase 4	70 participants (Actual)	Interventional	2009-01-31	Terminated (stopped due to Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012)
Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.[NCT00890214]	Phase 4	23 participants (Actual)	Interventional	2007-09-30	Completed
Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328]	Phase 4	14 participants (Actual)	Interventional	2007-02-28	Completed
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)[NCT02860130]	Phase 3	34 participants (Actual)	Interventional	2016-09-27	Terminated (stopped due to Study halted due to low recruitment, unrelated to safety or efficacy reasons)
Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial[NCT01269112]	Phase 4	103 participants (Actual)	Interventional	2010-11-30	Completed
Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.[NCT01228292]	Phase 4	250 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
[NCT02478242]	Phase 4	60 participants (Actual)	Interventional	2010-07-31	Completed
Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.[NCT02194569]		36 participants (Actual)	Interventional	2014-07-31	Completed
[NCT02423642]		30 participants (Actual)	Interventional	2013-07-31	Completed
Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming[NCT01486485]	Phase 3	160 participants (Anticipated)	Interventional	2012-03-31	Recruiting
[NCT01761994]	Phase 4	66 participants (Actual)	Interventional	2007-09-30	Completed
The Effect of Regional Citrate Anti-coagulation on the Coagulation System in Critically Ill Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury - an Observational Cohort Study[NCT02486614]		22 participants (Actual)	Observational	2014-06-30	Completed
Prismaflex Therapeutic Plasma Exchange: Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation[NCT04351438]		108 participants (Actual)	Observational	2012-01-31	Active, not recruiting
Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).[NCT00948558]		40 participants (Anticipated)	Observational	2009-03-31	Recruiting
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440]		30 participants (Anticipated)	Observational	2019-06-01	Active, not recruiting
Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients[NCT04353674]		40 participants (Anticipated)	Interventional	2020-04-28	Recruiting
[NCT01921816]		35 participants (Anticipated)	Interventional	2012-05-31	Completed
Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration[NCT00583765]		20 participants (Actual)	Observational	2005-04-30	Completed
HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification[NCT03312036]		12 participants (Actual)	Interventional	2013-06-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The primary endpoint for this study will be the difference in filter life in hours between the group receiving dilute heparin and the group receiving standard concentrated heparin. (NCT01318811)
Timeframe: 72 hours

Number of Major Bleeding Complications

Intervention	hours (Mean)
Dilute Heparin	22.46
Standard Concentrated Heparin	33

Information on major bleeding complications, and need for blood product transfusions will be collected. (NCT01318811)
Timeframe: 72 hours

Change From Baseline in Pulse at Last Visit

Intervention	clinical active major bleeding episodes (Number)
Dilute Heparin	0
Standard Concentrated Heparin	0

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Respiratory Rate at Last Visit

Intervention	beats/min (Mean)
Prismocitrate 18	2.1
No Systemic Anticoagulation	3.2

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Temperature at Last Visit

Intervention	breaths/Min (Mean)
Prismocitrate 18	-2.1
No Systemic Anticoagulation	-1.1

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Duration of Bleeding Events

Number of Investigator Site Facilities That Passed Prismocitrate 18 Training Assessment

Intervention	degree celsius (Mean)
Prismocitrate 18	0.2
No Systemic Anticoagulation	-0.1

Intervention	Hours (Mean)
Prismocitrate 18	0
No Systemic Anticoagulation	14.4

Training conducted on administration of Prismocitrate 18 to demonstrate the understanding of the user groups on how to use the solution by passing an assessment at the end of training. The user groups who needed to be assessed prior to use of Prismocitrate 18 in the clinical trial setting were to be comprised of physicians, nurses, and other clinicians who were part of prescribing, initiating or modifying treatment during the 120 hour Treatment Period. The training assessment was housed on a restricted access study website. Study personnel who completed the training assessment have a completion date listed which indicates that the individual received a passing score of 80% or better on the training assessment. (NCT02860130)
Timeframe: Prior to study use of Prismocitrate 18

Number of Participants Reporting Any Baxter Device/Product Related Adverse Events (Serious and Non-Serious)

Change From Baseline in Base Excess by Hour

Intervention	site facility staff (Number)
Prismocitrate 18	6

Intervention	Events (Number)
Prismocitrate 18	0
No Systemic Anticoagulation	1

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Blood Pressure at Last Visit

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	1.1	1.7	1.1	0.6	1.7	0.9	2.1	1.9	0.4	1.2	2.1	-2.1	4	3.7	3.1	2.2	-1.0	0.8	-2.8	-2.0
Prismocitrate 18	0.4	-1.3	0.3	2.4	1.3	3	2.8	2.4	1.3	3.7	3.2	3.6	2.5	4	3	3.5	1.6	3.5	2.7	2.8

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Blood Total Calcium Concentration by Hour

Intervention	mmHg (Mean)
	Systolic	Diastolic
No Systemic Anticoagulation	-6.4	2.8
Prismocitrate 18	1.9	-2.8

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Patient Ionized Calcium (iCa) by Hour

Intervention	mmol/L (Mean)
	1 Hour	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	-0.0	-0.0	-0.0	-0.0	-0.1	-0.0	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.2	-0.1	-0.2	-0.1	-0.1	-0.2	-0.1
Prismocitrate 18	-0.0	0.1	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.3	0.2	0.4

Systemic blood iCa concentrations (NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in pH by Hour

Intervention	mmol/L (Mean)
	1 Hour	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 hours	60 hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	0	0	0	0	-0.0	0	-0.0	0	0	-0.0	-0.0	-0.0	0	0	-0.0	-0.0	-0.0	0	0	0	-0.0
Prismocitrate 18	-0.1	-0.1	-0.0	0	0.1	0	0	0	0	0	0	-0.0	0	0	0	0	0	0	0	0.1	0.1

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Anion Gap by Hour

Intervention	pH (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0	0.1	-0.0	0
Prismocitrate 18	-0.0	-0.0	0	0	0	0	0	0	0	0	0.1	0	0	0.1	0	0	0	0	0	-0.0

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Bicarbonate by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	-2.3	-3.5	-2.2	-2.9	-3.6	-4	-3.5	-2.8	-3.2	-2.3	-3.2	0	-2.0	-3.0	-2.1	-1.7	-1.7	0.6	0.7	-1.2
Prismocitrate 18	0.6	0.6	0.2	-0.5	1.6	0.5	0.7	0.7	0.3	0.4	1.1	1	0.7	0.8	0.8	1.6	1.5	0.8	1	-0.3

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Chloride by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	2.4	2.9	2.3	2	2.9	2.6	3.6	2.4	2.1	2.4	2.6	0.1	2.9	2.5	2.2	1.4	-1.1	-0.4	-2.8	-1.5
Prismocitrate 18	0.2	0.8	1.3	2.8	2.9	3.3	3.3	2.7	2.7	4.7	3.7	4.2	2.8	3.3	3.3	2.8	2.2	2.7	3.8	2.8

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Magnesium by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	0.6	0.9	0.8	1.3	1.1	0.6	0.5	1.3	0.9	1	1	1.7	2.4	2.1	2.3	2.4	2.6	1.3	1.1	1
Prismocitrate 18	-1.9	-3.4	-3.9	-3.9	-5.5	-5.0	-4.9	-5.1	-5.4	-5.9	-5.3	-5.6	-5.5	-5.8	-5.9	-6.2	-6.0	-5.9	-7.7	-8.1

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Phosphate by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	0	-0.0	0	-0.0	0	0	0	0.1	0	0	0	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0
Prismocitrate 18	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.2	-0.2	-0.2	-0.1	-0.1	-0.1	-0.2	-0.2	-0.2	-0.2	-0.2	-0.2	-0.1	-0.2

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Potassium by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	-0.4	-0.4	-0.4	-0.4	-0.5	-0.4	-0.5	-0.4	-0.4	-0.4	-0.4	-0.2	-0.4	-0.4	-0.3	-0.5	-0.4	-0.4	0.2	-0.2
Prismocitrate 18	-0.3	-0.3	-0.5	-0.7	-0.6	-0.7	-0.8	-0.9	-0.8	-0.9	-0.8	-0.8	-0.8	-0.8	-0.8	-0.8	-0.7	-0.8	-0.9	-0.8

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Serum Sodium by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	-0.1	-0.1	-0.1	-0.2	-0.1	-0.0	-0.0	-0.0	0.1	0.1	0.3	0.2	0.1	0.2	0.2	0.2	0	0.1	0.2	0.1
Prismocitrate 18	-0.4	-0.4	-0.7	-0.9	-0.9	-1.0	-1.0	-1.0	-1.2	-1.2	-1.2	-1.2	-1.2	-1.3	-1.4	-1.1	-1.2	-1.2	-1.5	-1.1

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Change From Baseline in Total Calcium/iCa Ratio by Hour

Intervention	mmol/L (Mean)
	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	0.4	-0.1	0.5	0.4	0.4	-0.3	-0.4	1.2	0.5	1	0.3	2.5	2.6	1.7	2.2	2.3	1.1	0.7	1.4	1
Prismocitrate 18	-1.1	-1.6	-1.7	-1.7	-1.9	-1.1	-0.7	-1.5	-1.3	-1.3	-0.7	-0.8	-1.8	-2.2	-1.8	-2.0	-1.8	-2.4	-2.8	-3.7

(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation

Delivery of Prescribed CRRT Dose by Day

Intervention	ratio (Mean)
	1 Hour	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 Hours	60 Hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
No Systemic Anticoagulation	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1
Prismocitrate 18	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2

Evaluates the efficacy of using Prismocitrate 18 in delivering the prescribed CRRT dose, with delivered dose based on (daily) average effluent rate divided by (daily) average weight and expressed as mL/kg/hour. (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation

Extracorporeal Circuit Ionized Calcium by Hour

Intervention	mL/kg/hour (Mean)
	Day 1	Day 2	Day 3	Day 4	Day 5
No Systemic Anticoagulation	30.34	32.49	32.29	35.19	33.31
Prismocitrate 18	32.3	33.12	31.62	31.93	32.83

Post-filter blood iCa concentrations will only be measured in the Prismocitrate 18 arm. The extracorporeal circuit (post-filter). (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation

Number of Bleeding Events by Location

Number of Participants by Number of Blood Transfusions

Number of Participants With Bleeding Events

Time to Occurrence of Selected Prismaflex® System Alarms/Conditions

Intervention	mmol/L (Mean)
	1 Hour	6 Hours	12 Hours	18 Hours	24 Hours	30 Hours	36 Hours	42 Hours	48 Hours	54 hours	60 hours	66 Hours	72 Hours	78 Hours	84 Hours	90 Hours	96 Hours	102 Hours	108 Hours	114 Hours	120 Hours
Prismocitrate 18	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.5

Intervention	Events (Number)
	Gastrointestinal	M150 filter	ostomy and rectum	upper Gastrointestinal tract
No Systemic Anticoagulation	4	1	1	1
Prismocitrate 18	1	0	0	0

Intervention	participants (Number)
	3 Transfusions	27 Transfusions
No Systemic Anticoagulation	2	1
Prismocitrate 18	1	0

Intervention	Participants (Count of Participants)
	0 Bleeding Events	1 Bleeding Events	2 Bleeding Events	4 Bleeding Events
No Systemic Anticoagulation	13	3	0	1
Prismocitrate 18	16	1	0	0

"The point estimate is time point (number of hours of the extracorporeal circuit life of a filter) at which (100-percentile)% filters are still surviving (i.e. number surviving divided by number at risk), based on the Kaplan-Meier method. For example, for the 25th percentile: after 33.18 hours, 75% of filters are still surviving. Given the early termination, this study was not powered to show statistically significant changes in efficacy endpoints. The Prismaflex M150 Set extracorporeal circuit life of filters were intended to be assessed over a maximum of 120 hours (Treatment Period) by duration of time for which each Prismaflex M150 Set could be used continuously over a maximum 72 hour time-period in each patient. The end of the extracorporeal circuit life was defined by the occurrence of one or both of the following Prismaflex® System alarms/conditions if the alarms could not be mitigated: (1) Warning: Filter Clotted, and/or (2) Advisory transmembrane pressure (TMP) Too High." (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation

Intervention	hours (Number)
	25 Percentile	50 Percentile	75 Percentile
No Systemic Anticoagulation	17.680	29.660	NA
Prismocitrate 18	33.180	NA	NA

Article	Year
Ionic homeostasis, acid-base balance and the risk of citrate accumulation in patients after cardiovascular surgery treated with continuous veno-venous haemofiltration with post-dilution regional citrate anticoagulation - An observational case-control stud Acta biochimica Polonica, 2021, Oct-29, Volume: 68, Issue:4 Topics: Acid-Base Equilibrium; Acid-Base Imbalance; Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Ant	2021
[Effects of regional citrate anticoagulation in continuous veno-venous hemofiltration of severe burn patients]. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns, 2021, Dec-20, Volume: 37, Issue:12 Topics: Acute Kidney Injury; Adult; Anticoagulants; Burns; Citrates; Citric Acid; Continuous Renal Replaceme	2021
The effect of citrate in cardiovascular system and clot circuit in critically ill patients requiring continuous renal replacement therapy. Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2023, Volume: 26, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Cardiovascular System; Citrates; Citric Acid; Continuous Renal	2023
Analysis of Leukocyte Recruitment in Continuous Veno-Venous Hemofiltration with Regional Citrate vs. Systemic Heparin Anticoagulation. Cells, 2022, 06-01, Volume: 11, Issue:11 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; He	2022
Customized Citrate Anticoagulation versus No Anticoagulant in Continuous Venovenous Hemofiltration in Critically Ill Patients with Acute Kidney Injury: A Prospective Randomized Controlled Trial. Blood purification, 2023, Volume: 52, Issue:5 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; Cr	2023
Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Renal Replacement Therapy. Blood purification, 2023, Volume: 52, Issue:5 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Ther	2023
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 2020, 10-27, Volume: 324, Issue:16 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Continuous Renal Replacement Therap	2020
The effect of regional citrate anti-coagulation on the coagulation system in critically ill patients receiving continuous renal replacement therapy for acute kidney injury - an observational cohort study. BMC nephrology, 2017, Oct-02, Volume: 18, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citric Acid; Cohort Studies; Critical Illnes	2017
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial. BMJ open, 2019, 01-21, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Blood Transfusion; Citric Acid; Continuous Renal Replacement Th	2019
[The safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis]. Zhonghua nei ke za zhi, 2013, Volume: 52, Issue:6 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Citric Acid; Female; Humans; Kidney Failure, Chron	2013
Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs. BMC nephrology, 2013, Oct-25, Volume: 14 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Combined Modality Therapy; Female; Hemofiltr	2013
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical care (London, England), 2014, Aug-16, Volume: 18, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Critical Illness;	2014
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical care (London, England), 2014, Aug-16, Volume: 18, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Critical Illness;	2014
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical care (London, England), 2014, Aug-16, Volume: 18, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Critical Illness;	2014
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical care (London, England), 2014, Aug-16, Volume: 18, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Critical Illness;	2014
[Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis]. Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:12 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citrates; Citric Acid; Dialysis Solutions; F	2014
Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration. Blood purification, 2015, Volume: 39, Issue:4 Topics: Acute Kidney Injury; Adult; Anticoagulants; Blood Coagulation; Citric Acid; Dalteparin; Female; Hemo	2015
Citrate anticoagulation for continuous venovenous hemofiltration. Critical care medicine, 2009, Volume: 37, Issue:2 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He	2009
Citrate anticoagulation for continuous venovenous hemofiltration. Critical care medicine, 2009, Volume: 37, Issue:2 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He	2009
Citrate anticoagulation for continuous venovenous hemofiltration. Critical care medicine, 2009, Volume: 37, Issue:2 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He	2009
Citrate anticoagulation for continuous venovenous hemofiltration. Critical care medicine, 2009, Volume: 37, Issue:2 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He	2009
Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: a prospective sequential cohort study. Journal of critical care, 2010, Volume: 25, Issue:1 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Anticoagulants; Bicarbonates; Buffers; Calcium; Citric A	2010
A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure. Blood purification, 2010, Volume: 29, Issue:2 Topics: Acute Kidney Injury; Anticoagulants; Antigen-Presenting Cells; Atherosclerosis; Cardiovascular Disea	2010
Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15, Issue:6 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cell Degranulation;	2011
A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Renal failure, 2002, Volume: 24, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Blood Urea Nitrogen; Citric Acid; Combined Modalit	2002
Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive care medicine, 2004, Volume: 30, Issue:2 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citric Acid; Creatinine; Critical Care; Female; Hemofilt	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood purification, 2004, Volume: 22, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Burns; Calcium; Chemotherapy, Cancer, Regional Per	2004
A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. The International journal of artificial organs, 2007, Volume: 30, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Calcium; Citric Acid; Critical	2007
Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure. The International journal of artificial organs, 2008, Volume: 31, Issue:1 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Feasibility Studies; Female; Fondaparinux; H	2008
Recent advances in continuous renal replacement therapy: citrate anticoagulated continuous arteriovenous hemodialysis. ANNA journal, 1991, Volume: 18, Issue:3 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Blood Flow Velocity; Child; Citrates; Citric Acid; Fem	1991

Article	Year
Comparison of two regional citrate anticoagulation modalities for continuous renal replacement therapy by a prospective analysis of safety, workload, effectiveness, and cost. Minerva anestesiologica, 2021, Volume: 87, Issue:12 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; He	2021
Regional citrate anticoagulation high-cut-off continuous veno-venous hemodialysis for COVID-19 and AKI patients in intensive care unit. Clinical nephrology, 2021, Volume: 96, Issue:6 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; CO	2021
Development and External Validation of a Model for Predicting Sufficient Filter Lifespan in Anticoagulation-Free Continuous Renal Replacement Therapy Patients. Blood purification, 2022, Volume: 51, Issue:8 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Continuous Renal Replacement Therapy; Humans; Long	2022
Correcting hyponatremia by fluid sodium modulation in continuous renal replacement therapy with regional citrate anticoagulation. Seminars in dialysis, 2022, Volume: 35, Issue:2 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Ther	2022
Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy. Seminars in dialysis, 2022, Volume: 35, Issue:4 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Ther	2022
[Progress in the application of regional citrate anticoagulation in continuous renal replacement therapy in children]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2022, Mar-02, Volume: 60, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Child; Citrates; Citric Acid; Continuous Ren	2022
Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy. Pediatric nephrology (Berlin, Germany), 2022, Volume: 37, Issue:11 Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Child; Citrates; Citric Acid; Continuous Renal Re	2022
Immunomodulatory therapy using a pediatric dialysis system ameliorates septic shock in miniature pigs. Pediatric research, 2023, Volume: 93, Issue:1 Topics: Acute Kidney Injury; Animals; Anticoagulants; Citrates; Citric Acid; Immunomodulation; Renal Dialysi	2023
Semiautomated Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy: An Observational Study in Young Children. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2022, 09-01, Volume: 23, Issue:9 Topics: Acute Kidney Injury; Anticoagulants; Child; Child, Preschool; Citrates; Citric Acid; Continuous Rena	2022
Validation of a Protocol for Continuous Hemodiafiltration with Regional Citrate Anticoagulation with Omni®. Blood purification, 2022, Volume: 51, Issue:12 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Creatinine; Hemodiafiltration; Humans; R	2022
Comparison of different modalities of continuous renal replacement therapy with regional sodium citrate anticoagulation in paediatric patients. The International journal of artificial organs, 2022, Volume: 45, Issue:12 Topics: Acute Kidney Injury; Alkalosis; Anticoagulants; Child; Citric Acid; Continuous Renal Replacement The	2022
Clearance of Piperacillin-Tazobactam and Vancomycin During Continuous Renal Replacement With Regional Citrate Anticoagulation. Therapeutic drug monitoring, 2023, 04-01, Volume: 45, Issue:2 Topics: Acute Kidney Injury; Anti-Bacterial Agents; Anticoagulants; Citrates; Citric Acid; Critical Illness;	2023
Lessons for the clinical nephrologist: vascular access recirculation during continuous renal replacement therapy and regional citrate anticoagulation. Journal of nephrology, 2023, Volume: 36, Issue:2 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; Hu	2023
[Effectiveness of regional citrate anticoagulation in continuous renal replacement therapy]. Revista medica de Chile, 2022, Volume: 150, Issue:3 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Ther	2022
Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care. Journal of critical care, 2023, Volume: 74 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Critical Care; Heparin; Humans; R	2023
Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care. Journal of critical care, 2023, Volume: 74 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Critical Care; Heparin; Humans; R	2023
Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care. Journal of critical care, 2023, Volume: 74 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Critical Care; Heparin; Humans; R	2023
Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care. Journal of critical care, 2023, Volume: 74 Topics: Acute Kidney Injury; Adult; Anticoagulants; Citrates; Citric Acid; Critical Care; Heparin; Humans; R	2023
Impact of Continuous Veno-Venous HemoDiALYsis with Regional Citrate Anticoagulation on Non-NUTRItional Calorie Balance in Patients on the ICU-The NUTRI-DAY Study. Nutrients, 2022, Dec-23, Volume: 15, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Continuous Renal Replacement Therapy; Glucose; Hum	2022
Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC nephrology, 2023, 01-16, Volume: 24, Issue:1 Topics: Acute Kidney Injury; Adult; Anticoagulants; Blood Coagulation; Citric Acid; Continuous Renal Replace	2023
Simplified regional citrate anticoagulation protocol for CVVH, CVVHDF and SLED focused on the prevention of KRT-related hypophosphatemia while optimizing acid-base balance. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 09-29, Volume: 38, Issue:10 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal	2023
Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient. Scientific reports, 2023, 04-20, Volume: 13, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Critical Illness; Heparin; Humans; Hypop	2023
A simplified protocol of regional citrate anticoagulation with phosphate-containing solutions in infants and children treated with continuous kidney replacement therapy. Pediatric nephrology (Berlin, Germany), 2023, Volume: 38, Issue:11 Topics: Acute Kidney Injury; Adult; Anticoagulants; Child; Citrates; Citric Acid; Critical Illness; Hemofilt	2023
Factors affecting continuous renal replacement therapy duration in critically ill patients: A retrospective study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2023, Volume: 27, Issue:5 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; Cr	2023
Thromboelastography and Traditional Coagulation Testing in Non-ICU-Admitted Patients with Acute Kidney Injury: An Observational Cohort Study. American journal of nephrology, 2023, Volume: 54, Issue:5-6 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Cohort Studies; Fibrinogen; Heparin; Humans; Throm	2023
Quality indicators in prolonged hemodialysis with regional citrate anticoagulation with the genius system: retrospective cohort of critical patients with acute kidney injury. BMC nephrology, 2023, Nov-30, Volume: 24, Issue:1 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Critical Illness; Heparin; Humans; Quali	2023
Regional citrate anticoagulation with a substitute containing calcium for continuous hemofiltration in children. Medicine, 2019, Volume: 98, Issue:40 Topics: Acute Kidney Injury; Anticoagulants; Calcium; Child; Child, Preschool; Citric Acid; Female; Hemofilt	2019
Coupled-plasma filtration and adsorption for severe burn patients with septic shock and acute kidney injury treated with renal replacement therapy. Burns : journal of the International Society for Burn Injuries, 2020, Volume: 46, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Burns; Case-Control	2020
Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. Pharmacological reports : PR, 2020, Volume: 72, Issue:1 Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Anticoagulants; Chromatography, High Pressure Liqu	2020
Urinary NMR Profiling in Pediatric Acute Kidney Injury-A Pilot Study. International journal of molecular sciences, 2020, Feb-11, Volume: 21, Issue:4 Topics: Acute Kidney Injury; Adolescent; Biomarkers; Child; Child, Preschool; Citric Acid; Female; Humans; I	2020
[Research progress of the application of regional citrate anticoagulation in artificial liver to treat liver failure]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020, Jun-20, Volume: 28, Issue:6 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Heparin; Humans; Liver Failure; Liver, A	2020
Anticoagulation Strategies and Filter Life in COVID-19 Patients Receiving Continuous Renal Replacement Therapy: A Single-Center Experience. Clinical journal of the American Society of Nephrology : CJASN, 2020, 12-31, Volume: 16, Issue:1 Topics: Acute Kidney Injury; Aged; Anticoagulants; Arginine; Citric Acid; Continuous Renal Replacement Thera	2020
Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC nephrology, 2020, 11-16, Volume: 21, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Arginine; Betacoronavirus; Blood Coagulation; Citr	2020
Development, implementation and outcomes of a quality assurance system for the provision of continuous renal replacement therapy in the intensive care unit. Scientific reports, 2020, 11-26, Volume: 10, Issue:1 Topics: Acute Kidney Injury; Blood Coagulation; Citric Acid; Continuous Renal Replacement Therapy; Critical	2020
Continuous hemodialysis with citrate anticoagulation and standard dialysate for managing acute kidney injury in patients with moderate to severe hyponatremia-A retrospective study. Acta anaesthesiologica Scandinavica, 2021, Volume: 65, Issue:6 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Continuous Renal Replacement Therapy; Di	2021
Sustained low-efficiency dialysis with regional citrate anticoagulation in critically ill patients with COVID-19 associated AKI: A pilot study. Journal of critical care, 2021, Volume: 63 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citric Acid; COVID-19; Critical Care; Critic	2021
Dialysis circuit clotting in critically ill patients with COVID-19 infection. BMC nephrology, 2021, 04-20, Volume: 22, Issue:1 Topics: Acute Kidney Injury; Aged; Anticoagulants; Case-Control Studies; Citric Acid; Cohort Studies; Contin	2021
Continuous Renal-Replacement Therapy in Critically Ill Children: Practice Changes and Association With Outcome. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2021, 12-01, Volume: 22, Issue:12 Topics: Acute Kidney Injury; Child; Citric Acid; Continuous Renal Replacement Therapy; Critical Illness; Hum	2021
Electrolyte monitoring during regional citrate anticoagulation in continuous renal replacement therapy. Journal of clinical monitoring and computing, 2022, Volume: 36, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Bicarbonates; Calcium; Citrates; Citric Acid; Continuous Renal	2022
Continuous Renal Replacement Therapy with Low Dose Systemic Heparin in Liver Transplant Recipients. Iranian journal of kidney diseases, 2021, Volume: 15, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Continuous Renal Replacement Therapy; Critical Ill	2021
Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study. Critical care (London, England), 2021, 08-19, Volume: 25, Issue:1 Topics: Acute Kidney Injury; Adult; Citric Acid; Cohort Studies; Continuous Renal Replacement Therapy; COVID	2021
Hyperlactatemia Predicts Citrate Intolerance With Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy. Journal of intensive care medicine, 2019, Volume: 34, Issue:5 Topics: Acute Kidney Injury; Aged; Anticoagulants; APACHE; Citric Acid; Drug Tolerance; Female; Humans; Hype	2019
Citrate shows protective effects on cardiovascular and renal function in ischemia-induced acute kidney injury. BMC nephrology, 2017, 04-10, Volume: 18, Issue:1 Topics: Acute Kidney Injury; Adenosine Triphosphate; Animals; Anticoagulants; Blood Pressure; Calcium Glucon	2017
Safety and Efficacy of Citrate Anticoagulation for Continuous Renal Replacement Therapy for Acute Kidney Injury After Liver Transplantation: A Single-Center Experience. Transplantation proceedings, 2017, Volume: 49, Issue:4 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citric Acid; Female; Humans; Liver Transplan	2017
Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatric nephrology (Berlin, Germany), 2017, Volume: 32, Issue:10 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Child, Preschool; Citric Acid; Critical Illn	2017
Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients. The International journal of artificial organs, 2017, Nov-24, Volume: 40, Issue:12 Topics: Acute Kidney Injury; Aged; Anticoagulants; Blood Coagulation; Citric Acid; Critical Illness; Female;	2017
Complications of regional citrate anticoagulation: accumulation or overload? Critical care (London, England), 2017, Nov-19, Volume: 21, Issue:1 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Anticoagulants; Citric Acid; Humans; Intensive Care Unit	2017
Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD). International urology and nephrology, 2018, Volume: 50, Issue:6 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Dialysis Solutions; Electrolytes; F	2018
Use of regional citrate anticoagulation for continuous venovenous hemodialysis in critically ill cancer patients with acute kidney injury. Journal of critical care, 2018, Volume: 47 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Critical Care; Critical Illness; El	2018
Strong ion difference and CVVH: Different response during nadroparin versus citrate anticoagulation. Journal of critical care, 2018, Volume: 47 Topics: Acute Kidney Injury; Adult; Aged; Anesthesia; Anions; Anticoagulants; APACHE; Blood Coagulation; Cit	2018
A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding. Scientific reports, 2019, 04-29, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Blood Coagulation; Calcium; Citric Acid; Continuou	2019
A cost comparison of regional citrate versus low-dose systemic heparin anticoagulation in continuous renal replacement therapy. Anaesthesia and intensive care, 2019, Volume: 47, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Heparin; Humans; Renal Replacement Thera	2019
Feasibility and safety of combined cytokine adsorption and continuous veno-venous hemodialysis with regional citrate anticoagulation in patients with septic shock. The International journal of artificial organs, 2020, Volume: 43, Issue:1 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Adsorption; Aged; Anticoagulants; Citric Acid; Continuou	2020
Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2013, Volume: 17, Issue:2 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Citric Acid; Fe	2013
Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury. PloS one, 2013, Volume: 8, Issue:6 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Anticoagulants; Citric Acid; Critical Illness; Female;	2013
Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment. Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:10 Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Female; Humans; Male; Middle Aged; Renal Dia	2013
Citrate anticoagulation for continuous renal replacement therapy in small children. Pediatric nephrology (Berlin, Germany), 2014, Volume: 29, Issue:3 Topics: Acute Kidney Injury; Age Factors; Anticoagulants; Body Weight; Child, Preschool; Citric Acid; Critic	2014
Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. Journal of critical care, 2014, Volume: 29, Issue:2 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citrates; Citric Acid; Critical Illness; Female;	2014
Regional citrate anticoagulation for continuous renal replacement therapy in severe burns-a retrospective analysis of a protocol-guided approach. Burns : journal of the International Society for Burn Injuries, 2014, Volume: 40, Issue:8 Topics: Acute Kidney Injury; Aged; Anticoagulants; Body Surface Area; Burns; Citric Acid; Clinical Protocols	2014
A continuous veno-venous hemofiltration protocol with anticoagulant citrate dextrose formula A and a calcium-containing replacement fluid. The International journal of artificial organs, 2014, Volume: 37, Issue:6 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Blood Coagulation; Citric Acid; Dialysis Solutions	2014
Regional citrate anticoagulation for continuous renal replacement therapy in the perioperative care of liver transplant recipients: a single center experience. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2015, Volume: 19, Issue:1 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Anticoagulants; Citric Acid; Cohort Studies; Female; Gra	2015
Citrate for continuous renal replacement therapy: safer, better and cheaper. Critical care (London, England), 2014, Dec-03, Volume: 18, Issue:6 Topics: Acute Kidney Injury; Citric Acid; Female; Hemofiltration; Heparin; Humans; Male; Thrombosis	2014
Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy! Critical care (London, England), 2015, Feb-06, Volume: 19 Topics: Acute Kidney Injury; Citric Acid; Female; Hemofiltration; Heparin; Humans; Male; Thrombosis	2015
Coagulation, Fibrinolysis and Inhibitors in Failing Filters during Continuous Venovenous Hemofiltration in Critically Ill Patients with Acute Kidney Injury: Effect of Anticoagulation Modalities. Blood purification, 2015, Volume: 39, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagul	2015
Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:11 Topics: Acute Kidney Injury; Adsorption; Adult; Aged; Citric Acid; Female; Hemodiafiltration; Hemofiltration	2015
A Comparison between Two Dilute Citrate Solutions (15 vs. 18 mmol/l) in Continuous Renal Replacement Therapy: The Base Excess and Renal Substitution Solution Study. Blood purification, 2016, Volume: 42, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Hemofiltration; Humans; Prospective Stud	2016
Determinants of Calcium Infusion Rate During Continuous Veno-venous Hemofiltration with Regional Citrate Anticoagulation in Critically Ill Patients with Acute Kidney Injury. Chinese medical journal, 2016, Jul-20, Volume: 129, Issue:14 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Calcium; Citric Acid; Female; Hemofiltration; Huma	2016
Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: All Citrates Are Not Created Equal! Blood purification, 2016, Volume: 42, Issue:3 Topics: Acute Kidney Injury; Anticoagulants; Blood Coagulation; Citrates; Citric Acid; Heparin; Humans; Rena	2016
Chloride content of solutions used for regional citrate anticoagulation might be responsible for blunting correction of metabolic acidosis during continuous veno-venous hemofiltration. BMC nephrology, 2016, 08-26, Volume: 17, Issue:1 Topics: Acid-Base Equilibrium; Acidosis; Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Bicar	2016
Anticoagulation in Continuous Renal Replacement Therapy: Citrate Appears to Be Superior to Heparin! Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2016, Volume: 17, Issue:9 Topics: Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Heparin; Renal Dialysis; Renal Replaceme	2016
Citrate anticoagulation in the ICU: the Leeds experience. British journal of nursing (Mark Allen Publishing), 2016, Sep-08, Volume: 25, Issue:16 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Critical Illness; England; Hemorrhage; Heparin; Hu	2016
Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatric nephrology (Berlin, Germany), 2017, Volume: 32, Issue:4 Topics: Acute Kidney Injury; Adolescent; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Citric	2017
Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. The Annals of pharmacotherapy, 2009, Volume: 43, Issue:9 Topics: Acute Kidney Injury; Adult; Aged; Alkalosis; Anticoagulants; Calcium Gluconate; Citric Acid; Critica	2009
High cut-off membrane hemodiafiltration in myoglobinuric acute renal failure: a case series. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15, Issue:3 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Child; Citric Acid; Female; Hemodiafiltration; Hum	2011
Quantification of systemic delivery of substrates for intermediate metabolism during citrate anticoagulation of continuous renal replacement therapy. Blood purification, 2012, Volume: 33, Issue:1-3 Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Equipment Design; Glucose; Heparin; Humans; Lactic	2012
Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2012, Volume: 16, Issue:1 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium Gluconate; Citric Acid; Female; Hemodialysis Solu	2012
[Acute kidney injury: new insights from diagnostics and treatment]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:13 Topics: Acute Kidney Injury; Acute-Phase Proteins; Antibodies, Monoclonal, Humanized; Anticoagulants; Biomar	2012
[Continuous haemodialysis with citrate anticoagulation in patients with liver failure: three cases]. Annales francaises d'anesthesie et de reanimation, 2012, Volume: 31, Issue:6 Topics: Acute Kidney Injury; Anticoagulants; Calcium; Citric Acid; Fatal Outcome; Female; Hepatitis C; Human	2012
Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Critical care (London, England), 2012, Jun-27, Volume: 16, Issue:3 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Cardiac Surgical Pr	2012
Aluminum citrate prevents renal injury from calcium oxalate crystal deposition. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:12 Topics: Acute Kidney Injury; Animals; Calcium; Calcium Oxalate; Citric Acid; Drug Evaluation, Preclinical; E	2012
A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clinical nephrology, 2003, Volume: 59, Issue:2 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Calcium; Citric Acid; Female; Hemofiltration; Huma	2003
Low-dose citrate continuous veno-venous hemofiltration (CVVH) and acid-base balance. The International journal of artificial organs, 2005, Volume: 28, Issue:3 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Cohort Studies; Criti	2005
Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clinical chemistry and laboratory medicine, 2006, Volume: 44, Issue:8 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Citric Acid; Critical Illness; Drug Overdose; Fe	2006
Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations. Nephrology (Carlton, Vic.), 2006, Volume: 11, Issue:5 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Citric Acid; Female; Glucose; Hemofiltration; Huma	2006
Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 48, Issue:5 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Calcium; Citric Acid; Critical Illness; Female; He	2006
Continuous venovenous haemofiltration using a citrate buffered substitution fluid. Anaesthesia and intensive care, 2007, Volume: 35, Issue:4 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anticoagulants; Buffers;	2007
The acid-base effect of changing citrate solution for regional anticoagulation during continuous veno-venous hemofiltration. The International journal of artificial organs, 2008, Volume: 31, Issue:3 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Fem	2008
Gallium citrate Ga 67 scanning in acute renal failure. The Western journal of medicine, 1995, Volume: 162, Issue:5 Topics: Acute Disease; Acute Kidney Injury; Aged; Citrates; Citric Acid; Female; Gallium Radioisotopes; Huma	1995
Ibuprofen overdose complicated by renal failure, adult respiratory distress syndrome, and metabolic acidosis. Journal of toxicology. Clinical toxicology, 1994, Volume: 32, Issue:3 Topics: Acidosis; Acute Kidney Injury; Adult; Charcoal; Citrates; Citric Acid; Drug Overdose; Humans; Ibupro	1994
Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. Intensive care medicine, 1998, Volume: 24, Issue:3 Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Chelating Agents; Citric Acid; Hemodiafiltration	1998
Fatal hypermagnesemia. Clinical nephrology, 2000, Volume: 53, Issue:1 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Cathartics; Citric Acid; Fatal Outcome; Female; Humans	2000
Noninvasive monitoring of citrate, acetate, lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury. Cryobiology, 2000, Volume: 41, Issue:4 Topics: Acetic Acid; Acetylglucosaminidase; Acute Kidney Injury; Adenosine; Allopurinol; Animals; Biomarkers	2000
Calcium metabolism of brain in acute renal failure. Effects of uremia, hemodialysis, and parathyroid hormone. The Journal of clinical investigation, 1974, Volume: 53, Issue:2 Topics: Acute Disease; Acute Kidney Injury; Animals; Bicarbonates; Brain; Calcium; Citric Acid; Creatinine;	1974
Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months. Contributions to nephrology, 1991, Volume: 93 Topics: Acute Kidney Injury; Citrates; Citric Acid; Evaluation Studies as Topic; Hemofiltration; Hemorrhage;	1991
Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney international, 1990, Volume: 38, Issue:5 Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Citrates; Citric Acid; Female; Hemodialysis Soluti	1990
Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. The American journal of the medical sciences, 1989, Volume: 297, Issue:1 Topics: Acute Kidney Injury; Aged; Aluminum; Aluminum Hydroxide; Citrates; Citric Acid; Coma; Diabetes Compl	1989
Safety of regional citrate hemodialysis in acute renal failure. American journal of kidney diseases : the official journal of the National Kidney Foundation, 1989, Volume: 13, Issue:2 Topics: Acid-Base Equilibrium; Acute Kidney Injury; Anticoagulants; Citrates; Citric Acid; Creatinine; Femal	1989

citric acid, anhydrous and Acute Kidney Injury

Research Excerpts

Research

Studies (135)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

Filter Life

Number of Major Bleeding Complications

Change From Baseline in Pulse at Last Visit

Change From Baseline in Respiratory Rate at Last Visit

Change From Baseline in Temperature at Last Visit

Duration of Bleeding Events

Number of Investigator Site Facilities That Passed Prismocitrate 18 Training Assessment

Number of Participants Reporting Any Baxter Device/Product Related Adverse Events (Serious and Non-Serious)

Change From Baseline in Base Excess by Hour

Change From Baseline in Blood Pressure at Last Visit

Change From Baseline in Blood Total Calcium Concentration by Hour

Change From Baseline in Patient Ionized Calcium (iCa) by Hour

Change From Baseline in pH by Hour

Change From Baseline in Serum Anion Gap by Hour

Change From Baseline in Serum Bicarbonate by Hour

Change From Baseline in Serum Chloride by Hour

Change From Baseline in Serum Magnesium by Hour

Change From Baseline in Serum Phosphate by Hour

Change From Baseline in Serum Potassium by Hour

Change From Baseline in Serum Sodium by Hour

Change From Baseline in Total Calcium/iCa Ratio by Hour

Delivery of Prescribed CRRT Dose by Day

Extracorporeal Circuit Ionized Calcium by Hour

Number of Bleeding Events by Location

Number of Participants by Number of Blood Transfusions

Number of Participants With Bleeding Events

Time to Occurrence of Selected Prismaflex® System Alarms/Conditions

Reviews

Trials

Other Studies